Therapy Overview & Search
This is the search page for all therapy, you can search for name or condition
Filter By
Therapeutic Area
Manufacturer
SORT BY
-
Dupixent (dupilumab)
Dupxient (dupilumab) is a monoclonal antibody that blocks interleukin-4 receptor alpha to reduce inflammation in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, chronic spontaneous urticaria, and bullous pemphigoid.Manufacturer:Sanofi | RegeneronRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:phone:1-844-387-4936Approved Indication:
-
- treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
- add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma
- add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps
- treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kilograms, with eosinophilic esophagitis
- treatment of adult patients with prurigo nodularis
- add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease and an eosinophilic phenotype
- treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment
Conditions:
- Asthma
- Atopic Dermatitis
- Chronic Obstructive Pulmonary Disease
- Chronic Rhinosinusitis with Nasal Polyp
- Chronic Spontaneous Urticaria
- Eosinophilic Esophagitis
- Prurigo Nodularis
Therapeutic Area:
- Dermatology
- Gastroenterology
- Rheumatology
-
-
Endari (L-glutamine)
Endari (L-glutamine) is an amino acid supplement approved to reduce the complications of sickle cell disease.Manufacturer:Emmaus Medical, Inc.Route of Administration:OralSite of Care:OutpatientWebsite:phone:1-855-723-5646Approved Indication:
reduction of the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older
Conditions:
- Sickle Cell Disease
-
entecavir
Entecavir is an antiviral medication approved to treat chronic hepatitis B infections in patients with or without decompensated liver disease.Manufacturer:MiscRoute of Administration:OralSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease
Conditions:
- Chronic Viral Hepatitis B
Therapeutic Area:
- Gastroenterology
- Infectious Disease
- Hepatology
-
Entocort EC (budesonide)
Entocort EC (budesonide) is a synthetic corticosteroid formulated as a capsule that is used both to treat flares of Crohn’s disease and to maintain remission in certain parts of the gastrointestinal tract.Manufacturer:misc.Route of Administration:OralSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
- treatment of mild to moderate active Crohn’s disease involving the ileum and/or the ascending colon
Conditions:
- Crohn’s Disease
Therapeutic Area:
- Gastroenterology
-
Entyvio (vedolizumab)
Entyvio (vedolizumab) is an monoclonal antibody given by either infusion or injection that blocks the integrin receptor to reduce inflammation in inflammatory bowel diseases.Manufacturer:TakedaRoute of Administration:Intravenous, SubcutaneousSite of Care:OutpatientWebsite:Approved Indication:
- treatment of moderately to severely active ulcerative colitis
- treatment of moderately to severely active Crohn’s disease
Conditions:
- Crohn’s Disease
- Ulcerative Colitis
Therapeutic Area:
- Gastroenterology
-
Envarsus XR (tacrolimus extended-release)
Envarsus XR (tacrolimus extended-release) inhibits the enzyme calcineurin to decrease immune responsiveness and prevent rejection of a transplanted organ.Manufacturer:Veloxis PharmaceuticalsRoute of Administration:OralSite of Care:OutpatientWebsite:Approved Indication:
- prophylaxis of organ rejection in de novo kidney transplant patients in combination with other immunosuppressants
- prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants
Conditions:
- Solid Organ Transplant
Therapeutic Area:
- Hepatology
-
Epclusa (sofosbuvir/velpatasvir)
Epclusa (sofosbuvir/velpatasvir) is a combination of two antiviral medications approved to treat chronic hepatitis C infections in all patients regardless of hepatitis C genotype.Manufacturer:GileadRoute of Administration:OralSite of Care:OutpatientWebsite:Approved Indication:
treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis, with compensated cirrhosis, or with decompensated cirrhosis for use in combination with ribavirin
Conditions:
- Chronic Viral Hepatitis C
Therapeutic Area:
- Gastroenterology
- Hepatology
- Infectious Disease
-
Epogen (epoetin alfa)
Epogen (epoetin alfa) is a synthetic protein that promotes the production of new red blood cells in patients with certain types of anemia.Manufacturer:AmgenRoute of Administration:Subcutaneous, IntravenousSite of Care:OutpatientWebsite:phone:866-264-2778Enrollment Forms:Synergen Prescription FormApproved Indication:
- treatment of anemia due to chronci kidney disease in patients on dialysis and not on dialysis
- treatment of anemia due to zidovudine in patients with HIV infection
- treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy (upon initiation, a minimum of two additional months of planned chemotherapy required)
- reducing allogenic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery
Conditions:
- Anemia
Therapeutic Area:
- Nephrology
- Oncology
-
Esbriet (pirfenidone)
Esbriet (pirfenidone) is an antifibrotic medication that treats idiopathic pulmonary fibrosis by reducing the build-up of scar tissue in the lungs.Manufacturer:GenentechRoute of Administration:OralSite of Care:OutpatientWebsite:phone:888-941-3331Approved Indication:
treatment of idiopathic pulmonary fibrosis
Conditions:
- Idiopathic Pulmonary Fibrosis (IPF)
-
Exjade (deferasirox)
Exjade (deferoxamine) is an iron-chelating agent given orally to lower iron levels in the blood. The tablets must be dissolved in water, orange juice, or apple juice before administration.Manufacturer:NovartisRoute of Administration:OralSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
- treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older
- treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia syndromes and with a liver iron (Fe) concentration of at least 5mg Fe per gram of dry weight and a serum ferritin greater than 300mcg/L
Conditions:
- Sickle Celll Disease
- Anemia
- Non-Transfusion-Dependent Thalassemia
Therapeutic Area:
- Oncology
-
Feraheme (ferumoxytol)
Feraheme (ferumoxytol) is an iron oxide infusion used to treat anemia by supporting the formation of hemoglobin.Manufacturer:Amag PharmaceuticalsRoute of Administration:IntravenousSite of Care:OutpatientWebsite:phone:1-844-635-2624Approved Indication:
treatment of iron deficiency anemia in adult patients with chronic kidney disease
Conditions:
- Anemia
Therapeutic Area:
- Nephrology
-
Forteo (teriparatide)
Forteo (teriparatide) is a synthetic form of the natural human parathyroid hormone. Given by once-daily injection, it increases bone mineral density and strength to reduce the risk of fracture in patients with osteoporosis.Manufacturer:LillyRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:phone:1-866-568-8942Approved Indication:
- treatment of postmeopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to over available osteoporosis therapyy
- increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy
- treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy
Conditions:
- Osteoporosis